Libor Kostka

Dr. Libor Kostka

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
LWLieselotte Vande Walle
Lieselotte Vande Walle
ISIrma B. Stowe
Irma B. Stowe
PSPavel Sacha
Pavel Sacha
BLBettina L. Lee
Bettina L. Lee
DDDieter Demon
Dieter Demon
MLMohamed Lamkanfi
Mohamed Lamkanfi
The nucleotide-binding-domain (NBD)–and leucine-rich repeat (LRR)–containing (NLR) family, pyrin-domain–containing 3 (NLRP3) inflammasome drives pathological inflammation in a suite of autoimmune, metabolic, malignant, and neurodegenerative diseases. Additionally, NLRP3 gain-of-function point mutations cause systemic periodic fever syndromes that are collectively known as cryopyrin-associated periodic syndrome (CAPS). There is significant interest in the discovery and development of diarylsulfonylurea Cytokine Release Inhibitory Drugs (CRIDs) such as MCC950/CRID3, a potent and selective inhibitor of the NLRP3 inflammasome pathway, for the treatment of CAPS and other diseases. However, drug discovery efforts have been constrained by the lack of insight into the molecular target and mechanism by which these CRIDs inhibit the NLRP3 inflammasome pathway. Here, we show that the NAIP, CIITA, HET-E, and TP1 (NACHT) domain of NLRP3 is the molecular target of diarylsulfonylurea inhibitors. Interestingly, we find photoaffinity labeling (PAL) of the NACHT domain requires an intact (d)ATP-binding pocket and is substantially reduced for most CAPS-associated NLRP3 mutants. In concordance with this finding, MCC950/CRID3 failed to inhibit NLRP3-driven inflammatory pathology in two mouse models of CAPS. Moreover, it abolished circulating levels of interleukin (IL)-1β and IL-18 in lipopolysaccharide (LPS)-challenged wild-type mice but not in Nlrp3L351P knock-in mice and ex vivo-stimulated mutant macrophages. These results identify wild-type NLRP3 as the molecular target of MCC950/CRID3 and show that CAPS-related NLRP3 mutants escape efficient MCC950/CRID3 inhibition. Collectively, this work suggests that MCC950/CRID3-based therapies may effectively treat inflammation driven by wild-type NLRP3 but not CAPS-associated mutants.

29 October 2013 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RCRobert Crispin Carlisle
Robert Crispin Carlisle
JCJames Choi
James Choi
MBMiriam Bazan-Peregrino
Miriam Bazan-Peregrino
RLRichard Laga
Richard Laga
VSVladimir Subr
Vladimir Subr
LSLeonard W. Seymour
Leonard W. Seymour
Oncolytic viruses are among the most powerful and selective cancer therapeutics under development and are showing robust activity in clinical trials, particularly when administered directly into tumor nodules. However, their intravenous administration to treat metastatic disease has been stymied by unfavorable pharmacokinetics and inefficient accumulation in and penetration through tumors. Adenovirus (Ad) was “stealthed” with a new N -(2-hydroxypropyl)methacrylamide polymer, and circulation kinetics were characterized in Balb/C SCID mice (n = 8 per group) bearing human ZR-75-1 xenograft tumors. Then, to noninvasively increase extravasation of the circulating polymer-coated Ad into the tumor, it was coinjected with gas microbubbles and the tumor was exposed to 0.5 MHz focused ultrasound at peak rarefactional pressure of 1.2MPa. These ultrasound exposure conditions were designed to trigger inertial cavitation, an acoustic phenomenon that produces shock waves and can be remotely monitored in real-time. Groups were compared with Student t test or one-way analysis of variance with Tukey correction where groups were greater than two. All statistical tests were two-sided. Polymer-coating of Ad reduced hepatic sequestration, infection (>8000-fold; P < .001), and toxicity and improved circulation half-life (>50-fold; P = .001). Combination of polymer-coated Ad, gas bubbles, and focused ultrasound enhanced tumor infection >30-fold; (4×10 6 photons/sec/cm 2 ; standard deviation = 3×10 6 with ultrasound vs 1.3×10 5 ; standard deviation = 1×10 5 without ultrasound; P = .03) and penetration, enabling kill of cells more than 100 microns from the nearest blood vessel. This led to substantial and statistically significant retardation of tumor growth and increased survival. Combining drug stealthing and ultrasound-induced cavitation may ultimately enhance the efficacy of a range of powerful therapeutics, thereby improving the treatment of metastatic cancer.

10 February 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Petr ChytilPetr Chytil
Petr Chytil
LKLibor Kostka
Libor Kostka
Tomas EtrychTomas Etrych
Tomas Etrych
Recently, numerous polymer materials have been employed as drug carrier systems in medicinal research, and their detailed properties have been thoroughly evaluated. Water-soluble polymer carriers play a significant role between these studied polymer systems as they are advantageously applied as carriers of low-molecular-weight drugs and compounds, e.g., cytostatic agents, anti-inflammatory drugs, antimicrobial molecules, or multidrug resistance inhibitors. Covalent attachment of carried molecules using a biodegradable spacer is strongly preferred, as such design ensures the controlled release of the drug in the place of a desired pharmacological effect in a reasonable time-dependent manner. Importantly, the synthetic polymer biomaterials based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers are recognized drug carriers with unique properties that nominate them among the most serious nanomedicines candidates for human clinical trials. This review focuses on advances in the development of HPMA copolymer-based nanomedicines within the passive and active targeting into the place of desired pharmacological effect, tumors, inflammation or bacterial infection sites. Specifically, this review highlights the safety issues of HPMA polymer-based drug carriers concerning the structure of nanomedicines. The main impact consists of the improvement of targeting ability, especially concerning the enhanced and permeability retention (EPR) effect.

1 April 2009 in Journal of Controlled Release
Verified
Journal Article
Closed access
VŠV. Šubr
V. Šubr
LKLibor Kostka
Libor Kostka
TSTom Selby-Milic
Tom Selby-Milic
KFKerry Fisher
Kerry Fisher
KUKarel Ulbrich
Karel Ulbrich
RCRobert C. Carlisle
Robert C. Carlisle

1 January 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
ABAlena Braunová
Alena Braunová
LKLibor Kostka
Libor Kostka
LSLadislav Sivak
Ladislav Sivak
LCLucie Cuchalová
Lucie Cuchalová
ZHZuzana Hvězdová
Zuzana Hvězdová
Tomas EtrychTomas Etrych
Tomas Etrych

1 December 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
PCPetr Chytil
Petr Chytil
SHStefan Hoffmann
Stefan Hoffmann
LSLucie Schindler
Lucie Schindler
LKLibor Kostka
Libor Kostka
KUKarel Ulbrich
Karel Ulbrich
TETomáš Etrych
Tomáš Etrych